Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the transaction price of ADSs, which was $44.242 per ADS.
Material Changes
The filing details increases in share interests for specific directors and connected persons resulting from the re-investment of dividends paid to shareholders on January 3, 2013. There are no reported material changes to the company's financial position or operations in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of insider share transactions.
Important Facts for Investors
- Directors and PDMRs increased their ADS holdings via dividend re-investment at a price of $44.242 per ADS.
- Specific increases included Dr. M M Slaoui (799.925 ADSs), Mrs. D P Connelly (388.380 ADSs), Mr. W C Louv (208.461 ADSs), and Mr. D E Troy (199.632 ADSs).
- Dr. K Slaoui, a connected person, increased holdings by 14.266 ADSs.
- The company was advised of these transactions on January 9, 2013, and the report was signed on January 10, 2013.